A Trial Evaluating Brelovitug (BJT-778) vs Bulevirtide for the Treatment of Chronic Hepatitis Delta Infection (AZURE-2)

Recruiting now · Phase 3

Conditions studied: Chronic Hepatitis D Infection

In brief

This is a Phase 3, global, randomized, open-label, multicenter, trial evaluating brelovitug (BJT-778) vs bulevirtide for the treatment of chronic hepatitis delta infection (CHD). The main goal of this study is to test the effectiveness of brelovitug compared to bulevirtide as a long-term treatment in patients with chronic HDV infection.

Key facts

Study ID
NCT07200908
Run by
Mirum Pharmaceuticals, Inc.
People needed
172
Starts
2025-08-27
Expected to finish
2029-09-30
Last updated by the study team
2026-06-15

Who can join

Age: 18 and older, up to 99. Sex: any. Healthy volunteers: not accepted.

Where it is running

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.